应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
NVO 诺和诺德
休市中 06-05 16:00:00 EDT
42.96
-0.79
-1.81%
盘后
42.73
-0.23
-0.54%
19:59 EDT
最高
44.22
最低
42.86
成交量
1,086万
今开
44.05
昨收
43.75
日振幅
3.12%
总市值
1,907亿
流通市值
1,370亿
总股本
44.39亿
成交额
4.71亿
换手率
0.34%
流通股本
31.88亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
诺和诺德：司美格鲁肽2毫克在一年期试验中，糖化血红蛋白达标率与替尔泊肽相当，减重达标率更优
美股速递 · 06-06 21:04
诺和诺德：司美格鲁肽2毫克在一年期试验中，糖化血红蛋白达标率与替尔泊肽相当，减重达标率更优
需求扩容抵消降价压力 GLP-1赛道远期市场空间再度上调
金吾财讯 · 06-05 23:18
需求扩容抵消降价压力 GLP-1赛道远期市场空间再度上调
礼来、诺和诺德涨超5%，多项并购、研发进展及产能优化利好共振
异动解读 · 06-04
礼来、诺和诺德涨超5%，多项并购、研发进展及产能优化利好共振
异动解读｜诺和诺德盘中上涨3.12%，制药板块集体走强叠加口服Wegovy海外拓展提振
行情直击 · 06-04
异动解读｜诺和诺德盘中上涨3.12%，制药板块集体走强叠加口服Wegovy海外拓展提振
诺和诺德在阿联酋上市维格维口服减肥药，系美国以外首个落地市场
环球市场播报 · 06-03
诺和诺德在阿联酋上市维格维口服减肥药，系美国以外首个落地市场
异动解读｜诺和诺德盘中下跌3.17%，制药板块持续走弱叠加减肥药竞争格局恶化
行情直击 · 06-02
异动解读｜诺和诺德盘中下跌3.17%，制药板块持续走弱叠加减肥药竞争格局恶化
异动解读｜诺和诺德盘中下跌3.09%，制药板块整体承压叠加减肥药竞争格局恶化
行情直击 · 06-01
异动解读｜诺和诺德盘中下跌3.09%，制药板块整体承压叠加减肥药竞争格局恶化
Gate 股票衍生品专区将首发上线 NVO（诺和诺德）、NOK（诺基亚）等 6 个永续合约交易
链捕手 · 06-01
Gate 股票衍生品专区将首发上线 NVO（诺和诺德）、NOK（诺基亚）等 6 个永续合约交易
诺和诺德：印度批准维格维用于青少年群体
环球市场播报 · 05-29
诺和诺德：印度批准维格维用于青少年群体
异动解读｜诺和诺德盘中上涨3.18%，EASL大会MASH数据发布叠加收购传闻提振
行情直击 · 05-28
异动解读｜诺和诺德盘中上涨3.18%，EASL大会MASH数据发布叠加收购传闻提振
诺和诺德高剂量Wegovy单剂量注射笔获欧盟CHMP积极意见
环球市场播报 · 05-23
诺和诺德高剂量Wegovy单剂量注射笔获欧盟CHMP积极意见
诺和诺德(NVO)Wegovy获欧洲背书 GLP1赛道竞争持续升温
金吾财讯 · 05-22
诺和诺德(NVO)Wegovy获欧洲背书 GLP1赛道竞争持续升温
减重神药或能抑制癌症发展，诺和诺德、礼来迎重磅利好
华尔街见闻 · 05-22
减重神药或能抑制癌症发展，诺和诺德、礼来迎重磅利好
诺和诺德计划推动Wegovy口服减肥药登陆美国以外市场
环球市场播报 · 05-18
诺和诺德计划推动Wegovy口服减肥药登陆美国以外市场
减重赛道激战正酣：跨国巨头齐亮剑，竞争升维至全病程管理
21世纪经济报道 · 05-13
减重赛道激战正酣：跨国巨头齐亮剑，竞争升维至全病程管理
市场聚焦：游戏驿站、Venture Global、温蒂汉堡、Hims & Hers等个股动态
投资观察 · 05-12
市场聚焦：游戏驿站、Venture Global、温蒂汉堡、Hims & Hers等个股动态
关注焦点：Venture Global、Hims & Hers、GoPro等个股动态
投资观察 · 05-12
关注焦点：Venture Global、Hims & Hers、GoPro等个股动态
扎克伯格投资生物药企拿下诺和诺德细胞疗法
第一财经 · 05-12
扎克伯格投资生物药企拿下诺和诺德细胞疗法
诺和诺德(NVO.US)在印度降价后 减肥药销量4月激增40%
智通财经 · 05-08
诺和诺德(NVO.US)在印度降价后 减肥药销量4月激增40%
跨国药企开门红 巨头领跑减重赛道 “王牌”产品成增长胜负手
21世纪经济报道 · 05-08
跨国药企开门红 巨头领跑减重赛道 “王牌”产品成增长胜负手
加载更多
公司概况
公司名称：
诺和诺德
所属市场：
NYSE
上市日期：
--
主营业务：
Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球性的医疗保健公司，也是肥胖和糖尿病护理、制造和营销包括GLP-1受体激动剂和现代胰岛素在内的医药产品的世界领先企业。总部位于丹麦，业务遍及约80个国家，产品销往约170个国家。
发行价格：
--
{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":42.96,"timestamp":1780689600000,"preClose":43.75,"halted":0,"volume":10855623,"hourTrading":{"tag":"盘后","latestPrice":42.73,"preClose":42.96,"latestTime":"19:59 EDT","volume":463671,"amount":19906158.5455,"timestamp":1780703985313,"change":-0.23,"changeRate":-0.005354,"amplitude":0.007682},"delay":0,"changeRate":-0.018057142857142838,"floatShares":3187922885,"shares":4439052849,"eps":4.228648,"marketStatus":"休市中","change":-0.79,"latestTime":"06-05 16:00:00 EDT","open":44.05,"high":44.22,"low":42.855,"amount":471001273.93071,"amplitude":0.0312,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.228648,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1780905600000},"marketStatusCode":7,"adr":1,"adrRate":1,"listingDate":363499200000,"exchange":"NYSE","adjPreClose":43.75,"dividendRate":0.040082,"preHourTrading":{"tag":"盘前","latestPrice":43.99,"preClose":43.75,"latestTime":"09:29 EDT","volume":123496,"amount":5445907.219128,"timestamp":1780666197196,"change":0.24,"changeRate":0.005486,"amplitude":0.015314},"postHourTrading":{"tag":"盘后","latestPrice":42.73,"preClose":42.96,"latestTime":"19:59 EDT","volume":463671,"amount":19906158.5455,"timestamp":1780703985313,"change":-0.23,"changeRate":-0.005354,"amplitude":0.007682},"volumeRatio":0.7878640310731022,"impliedVol":0.4209,"impliedVolPercentile":0.0837},"requestUrl":"/m/hq/s/NVO","defaultTab":"news","newsList":[{"id":"1180373682","title":"诺和诺德：司美格鲁肽2毫克在一年期试验中，糖化血红蛋白达标率与替尔泊肽相当，减重达标率更优","url":"https://stock-news.laohu8.com/highlight/detail?id=1180373682","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180373682?lang=zh_cn&edition=full","pubTime":"2026-06-06 21:04","pubTimestamp":1780751047,"startTime":"0","endTime":"0","summary":"诺和诺德公司研发的司美格鲁肽2毫克剂量，在一项为期一年的临床试验数据中，展现出与礼来公司替尔泊肽在关键血糖控制指标上的同等效力，并在减重效果上实现了超越。\n具体数据显示，接受司美格鲁肽2毫克治疗的患者，其糖化血红蛋白水平成功降至7%以下的比例，与使用替尔泊肽的患者群体相当。然而，在衡量减重效果的另一个关键终点上，司美格鲁肽表现更为突出：治疗一年后，实现体重减轻至少5%的患者比例显著高于替尔泊肽组。\n这一对比结果，为评估这两款在糖尿病与肥胖症治疗领域占据重要地位的药物提供了新的临床依据，凸显了司美格鲁肽在促进显著减重方面的潜在优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0432979614.USD","LU1548497426.USD","LU0238689110.USD","LU1035775433.USD","BK4533","LU2461242641.AUD","LU1989771016.USD","BK4585","LU2028103732.USD","LU2756315664.SGD","LU0456855351.SGD","LU0689472784.USD","LU0466842654.USD","LU2168564149.EUR","SG9999015978.USD","LU0823416689.USD","LU1623119135.USD","LU1127390331.HKD","IE00B4R5TH58.HKD","LU0109391861.USD","LU0154236417.USD","LU2168564065.EUR","IE00BJT1NW94.SGD","LU2168564222.USD","LU2213496289.HKD","IE00BFSS7M15.SGD","LU2357305700.SGD","BK4534","LU2471134523.USD","LU0964807845.USD","IE00BJJMRY28.SGD","BK4581","LU2265009873.SGD","LU2087625088.SGD","SG9999018865.SGD","LLY","LU0820561909.HKD","LU0943347566.SGD","SG9999001176.USD","SGXZ99366536.SGD","LU1093756168.USD","LU1868836591.USD","IE0002141913.USD","LU2237443382.USD","LU1814569148.SGD","LU1868836757.USD","LU1974910355.USD","LU2552382132.HKD","LU2468319806.SGD","IE00BJJMRX11.SGD","LU1868836914.USD","LU1280957306.USD","LU0058720904.USD","LU2236285917.USD","IE0009355771.USD","IE00BKVL7J92.USD","LU0106261372.USD","LU1057294990.SGD","LU1720051108.HKD","LU2896262040.SGD","LU0385154629.USD","SG9999018857.SGD","LU2361044949.HKD","SGXZ57979304.SGD","LU0316494557.USD","IE00BKDWB100.SGD","LU1145028129.USD","SG9999015945.SGD","LU1712237335.SGD","LU2106854487.HKD","LU0353189680.USD","LU1917777945.USD","LU0198837287.USD","LU0006306889.USD","LU2750360641.GBP","LU0225283273.USD","IE00BFTCPJ56.SGD","LU0133085943.USD","SG9999014898.SGD","LU1232071149.USD","SG9999014914.USD","LU2211815571.USD","LU2756315318.SGD","LU0320765992.SGD","SG9999014880.SGD","LU0094547139.USD","IE00BN29S564.USD","IE00B7KXQ091.USD","LU1983299246.USD","LU2237443622.USD","LU2271345857.HKD","LU0114720955.EUR","LU0354030438.USD","LU0417517546.SGD","LU2168563687.JPY","LU0823434740.USD","LU1069344957.HKD","BK4532","IE0004445239.USD","LU0266013472.USD","LU2168564495.EUR","LU1323610961.USD","IE00BK4W5M84.HKD","LU0889565916.HKD","LU0823434583.USD","LU2491050071.SGD","LU0061475181.USD","SGXZ81514606.USD","LU0672654240.SGD","SG9999001176.SGD","LU2023250504.SGD","LU2552382215.SGD","LU1366192091.USD","LU2237438978.USD","ELIL","LU1551013342.USD","LU2746668974.SGD","LU0786609619.USD","LU2462157665.USD","LU1061106388.HKD","LU1804176565.USD","LU2111349929.HKD","LU0256863811.USD","LU2237443895.HKD","IE00B1XK9C88.USD","IE0004445015.USD","LU0320765059.SGD","LU2471134796.USD","IE00B1BXHZ80.USD","LU1868837136.USD","SGXZ31699556.SGD","BK4007","LLYX","LU2089984988.USD","IE00BJLML261.HKD","NVOX","IE00BZ1G4Q59.USD","LU2491049909.HKD","LU2750360997.AUD","LU1023059063.AUD","BK4516","LU0109394709.USD","LU0096364046.USD","IE00BFSS8Q28.SGD","LU0353189763.USD","LU2552382058.USD","LU2063271972.USD","IE00BK4W5L77.USD","LU0097036916.USD","LU2360106947.USD","LU2089283258.USD","LU0079474960.USD","BK4588","GB00BDT5M118.USD","LU0256863902.USD","LU2023251221.USD","LU0234572021.USD","LU1868837300.USD","BK4599","LU2112291526.USD","LU2471134879.HKD","LU2746668461.USD","LU2089284900.SGD","LU2456880835.USD","LU0158827781.USD","LU2417539215.USD","SG9999013999.USD","LU2324357040.USD","LU2361044865.SGD","LU2237443465.HKD","IE00BKPKM429.USD","LU0122379950.USD","SGXZ51526630.SGD","IE00BJJMRZ35.SGD","LU2237443978.SGD","LU0158827948.USD","LU1267930730.SGD","LU2471134952.CNY","LU1093756325.SGD","SG9999014906.USD","LU0203201768.USD","ELIS","SG9999017495.SGD","LU0323591593.USD","LU0882574055.USD","LU0471298777.SGD","SG9999015986.USD","IE0005OL40V9.USD","LLYZ","LU2023250330.USD","LU2602419157.SGD","NVO","LU0471298694.HKD","LU0882574139.USD","LU0683600562.USD","IE00BWXC8680.SGD","LU1629891620.HKD","LU2264538146.SGD","LU0210536198.USD","LU0354030511.USD","LU0820562030.AUD","LU0203202063.USD","LLII","IE00B2B36J28.USD","NVOH","IE00B775H168.HKD","LU2491050154.USD","LU0640476718.USD","LU2237443549.SGD","LU0708995401.HKD","LU1064131342.USD","IE00B4JS1V06.HKD","LU2108987350.USD","LU2361045086.USD","LU1551013425.SGD","LU1988902786.USD","LU0820561818.USD","SG9999015952.SGD","LU1720051017.SGD","LU0787776722.HKD","IE0001KFT4U8.USD","LU1291159041.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641149941","title":"需求扩容抵消降价压力 GLP-1赛道远期市场空间再度上调","url":"https://stock-news.laohu8.com/highlight/detail?id=2641149941","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641149941?lang=zh_cn&edition=full","pubTime":"2026-06-05 23:18","pubTimestamp":1780672735,"startTime":"0","endTime":"0","summary":"金吾财讯 | TD Cowen上调GLP-1药物赛道远期市场预期，预计2030年全球GLP-1药物销售额将达1500亿美元，较此前1390亿美元的预测上调8%，较早年1010亿美元预期大幅抬升。需求端增量是赛道核心支撑，该机构预计2030年全球受益患者规模将从4600万增至5900万，用药需求扩容可对冲行业降价带来的营收压力。今年落地的口服GLP-1制剂商业化潜力突出，预计2030年有望占据全球总销售额的14%。","market":"other","thumbnail":"https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301232","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GB00BDT5M118.USD","LU0466842654.USD","LU0943347566.SGD","BK4581","LU2491050071.SGD","LU2237443465.HKD","LU2602419157.SGD","LU2213496289.HKD","LU0708995401.HKD","BK4532","LU0320765992.SGD","IE00BJLML261.HKD","LU2471134879.HKD","LU0471298777.SGD","LU2361044865.SGD","SG9999015986.USD","IE00BK4W5L77.USD","LU2108987350.USD","LU2264538146.SGD","LU0097036916.USD","IE0004445015.USD","LU1551013425.SGD","IE0001KFT4U8.USD","LU2750360641.GBP","LU1127390331.HKD","SG9999015945.SGD","BK4599","IE00B4JS1V06.HKD","LU2417539215.USD","LU2552382132.HKD","SG9999013999.USD","LU2089284900.SGD","LU1069344957.HKD","LU2089283258.USD","SG9999015952.SGD","SGXZ51526630.SGD","LU0823434583.USD","LU0456855351.SGD","LU2028103732.USD","LU2023250504.SGD","LU0820561818.USD","LU0882574139.USD","LU0058720904.USD","LU0225283273.USD","LU0640476718.USD","IE00BJJMRZ35.SGD","LU2456880835.USD","LU1057294990.SGD","LU2462157665.USD","LU0417517546.SGD","LU1145028129.USD","LU1988902786.USD","LU2491050154.USD","IE00BKVL7J92.USD","LU0353189680.USD","LU2237443549.SGD","LU0234572021.USD","LU1366192091.USD","LU1868837300.USD","LU0154236417.USD","LU1720051017.SGD","IE0005OL40V9.USD","LU1804176565.USD","IE00BKPKM429.USD","LU1868837136.USD","SG9999015978.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","LU0672654240.SGD","IE00B1XK9C88.USD","LU1868836591.USD","LU0006306889.USD","LU1623119135.USD","IE00BJJMRY28.SGD","IE00BFSS8Q28.SGD","LU0889565916.HKD","IE00BKDWB100.SGD","LU1267930730.SGD","LU2089984988.USD","LU2112291526.USD","LU2552382215.SGD","LU2236285917.USD","LU0820562030.AUD","LU0158827781.USD","LLYZ","IE00BWXC8680.SGD","LU0353189763.USD","LU0354030511.USD","LU1720051108.HKD","LU1917777945.USD","SGXZ57979304.SGD","IE0009355771.USD","LU0133085943.USD","BK4007","LU0203201768.USD","LU0683600562.USD","LU2023250330.USD","LLY","IE00BK4W5M84.HKD","LU1023059063.AUD","LU0096364046.USD","LU2063271972.USD","LU2471134952.CNY","LU0320765059.SGD","IE00BZ1G4Q59.USD","LU1868836914.USD","LU0158827948.USD","LU0256863811.USD","LLYX","LU2106854487.HKD","LU2361045086.USD","LU2168564149.EUR","LU1064131342.USD","LU1814569148.SGD","LU0964807845.USD","LU0256863902.USD","LU2237443895.HKD","LU0210536198.USD","LU2746668461.USD","SG9999014880.SGD","LU0289739699.SGD","LU2023251221.USD","LU2168563687.JPY","SG9999018865.SGD","SG9999001176.SGD","LU0432979614.USD","LU0061475181.USD","ELIS","LU0109394709.USD","IE00B7KXQ091.USD","LU2360106947.USD","LU1989771016.USD","LU0316494557.USD","LU1548497426.USD","LU0203202063.USD","LU2461242641.AUD","LU0354030438.USD","LU0114720955.EUR","LU2471134523.USD","LU2168564495.EUR","LU2168564065.EUR","LU1280957306.USD","LU0323591593.USD","IE00B2B36J28.USD","LU2552382058.USD","ELIL","LU2746668974.SGD","LU2265009873.SGD","SG9999018857.SGD","LU2896262040.SGD","LU0689472784.USD","LU2471134796.USD","LU0786609619.USD","LU1323610961.USD","BK4533","LU2211815571.USD","SG9999001176.USD","BK4585","SGXZ81514606.USD","LU0266013472.USD","IE00BFSS7M15.SGD","NVOH","IE0004445239.USD","LU1061106388.HKD","BK4588","LU1629891620.HKD","SG9999014906.USD","IE00BN29S564.USD","LU0198837287.USD","LU1093756325.SGD","LU1232071149.USD","BK4516","SGXZ99366536.SGD","LU2087625088.SGD","BK4534","LU2271345857.HKD","SGXZ31699556.SGD","LU0106261372.USD","LU2756315664.SGD","NVOX","LU2361044949.HKD","IE00BFTCPJ56.SGD","LU1974910355.USD","LU0385154629.USD","LU2756315318.SGD","LU2491049909.HKD","LU2237438978.USD","LU0122379950.USD","LU2750360997.AUD","LU0471298694.HKD","LU1551013342.USD","LU1868836757.USD","LLII","LU2357305700.SGD","NVO","LU0109391861.USD","LU0820561909.HKD","LU0823434740.USD","LU0823416689.USD","LU2168564222.USD","LU1093756168.USD","LU0882574055.USD","LU1712237335.SGD","IE0002141913.USD","LU0787776722.HKD","LU2237443622.USD","IE00BJJMRX11.SGD","LU2324357040.USD","LU2237443382.USD","LU1291159041.SGD","IE00B1BXHZ80.USD","LU0079474960.USD","IE00B775H168.HKD","LU0094547139.USD","IE00B4R5TH58.HKD","SG9999017495.SGD","LU1035775433.USD","SG9999014898.SGD","SG9999014914.USD","LU1983299246.USD","LU2111349929.HKD","LU2237443978.SGD","LU0238689110.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185465612","title":"礼来、诺和诺德涨超5%，多项并购、研发进展及产能优化利好共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1185465612","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185465612?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:57","pubTimestamp":1780585052,"startTime":"0","endTime":"0","summary":"近期利好频传。","market":"us","thumbnail":"https://static.tigerbbs.com/383539e68cf14d4cde7a90d97b6a4424","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/383539e68cf14d4cde7a90d97b6a4424"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"986bfebb17fba902db75e9cba66f1f6a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOX","NVOH","LLY","NVO"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1169829532","title":"异动解读｜诺和诺德盘中上涨3.12%，制药板块集体走强叠加口服Wegovy海外拓展提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1169829532","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169829532?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:16","pubTimestamp":1780582564,"startTime":"0","endTime":"0","summary":"6月4日，诺和诺德盘中上涨3.12%，报43.94美元/股，成交额1.44亿美元。消息面上，制药板块集体走强，礼来涨4.05%、默沙东涨4.04%、施贵宝涨3.25%、辉瑞涨1.95%，诺和诺德跟随板块反弹，此前连续两个交易日回调后迎来修复。此外，近期多重利好持续发酵：诺和诺德与合作伙伴Metabolic宣布阿联酋将成为美国以外首个获得口服版Wegovy的市场，临床试验显示口服版64周内平均减重17%；印度亦已批准Wegovy用于12岁及以上青少年群体，适应症拓展持续推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640970210","title":"诺和诺德在阿联酋上市维格维口服减肥药，系美国以外首个落地市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2640970210","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640970210?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:28","pubTimestamp":1780478880,"startTime":"0","endTime":"0","summary":"诺和诺德于阿联酋推出减肥口服药维格维。这是该款药片在美国本土之外的首个上市市场。 这家丹麦药企周三宣布，减肥口服药维格维正式登陆阿联酋，这也是该药品首次在美国以外地区上市。 诺和诺德在 5 月初发布一季报时曾透露，在取得各国药监审批后，将于 2026 年下半年在部分海外国家上市这款口服减肥药，当时未披露具体落地国家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-03/doc-iniacnuq4163888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","NVOX","LU1093756325.SGD","BK4007","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","NVO","BK4532","NVOH","BK4599","BK4585","LU0154236417.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154647672","title":"异动解读｜诺和诺德盘中下跌3.17%，制药板块持续走弱叠加减肥药竞争格局恶化","url":"https://stock-news.laohu8.com/highlight/detail?id=1154647672","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154647672?lang=zh_cn&edition=full","pubTime":"2026-06-02 22:19","pubTimestamp":1780409990,"startTime":"0","endTime":"0","summary":"6月2日，诺和诺德盘中下跌3.17%，报43.425美元/股，成交额3.01亿美元。消息面上，制药板块整体承压，礼来跌1.31%、辉瑞跌0.9%、Zoetis跌1.47%，诺和诺德跟随板块延续弱势。此外，减肥药赛道竞争格局持续恶化：礼来三重激动剂瑞他鲁肽三期数据显示最高减重28.3%，大幅领先诺和诺德CagriSema的22.7%；巴西已批准Ozempic仿制药上市，售价低30%，定价压力加剧。市场对诺和诺德管线竞争力的担忧延续，股价连续两个交易日承压回调。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188955592","title":"异动解读｜诺和诺德盘中下跌3.09%，制药板块整体承压叠加减肥药竞争格局恶化","url":"https://stock-news.laohu8.com/highlight/detail?id=1188955592","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188955592?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:45","pubTimestamp":1780325132,"startTime":"0","endTime":"0","summary":"6月1日，诺和诺德盘中下跌3.09%，报44.18美元/股，成交额1.73亿美元。消息面上，制药板块整体走弱，行业内默沙东跌3.1%、施贵宝跌3.66%、礼来跌2.53%，诺和诺德跟随板块回调。此外，近期多重竞争压力持续发酵：礼来三重激动剂瑞他鲁肽三期数据显示最高减重28.3%，大幅领先诺和诺德CagriSema的22.7%；巴西已批准Ozempic仿制药上市，售价低30%，加剧定价压力。减肥药赛道竞争格局持续向礼来倾斜，市场对诺和诺德管线竞争力的担忧延续。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640339909","title":"Gate 股票衍生品专区将首发上线 NVO（诺和诺德）、NOK（诺基亚）等 6 个永续合约交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2640339909","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640339909?lang=zh_cn&edition=full","pubTime":"2026-06-01 13:39","pubTimestamp":1780292398,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据官方消息，Gate 股票衍生品专区将于 6 月 1 日 14:00（UTC+8）首发上线 NVO（诺和诺德）、NOK（诺基亚）、ASTS（AST 太空移动）、AAOI（应用光电）、INFQ (Infleqtion)、CRWD（众击）永续合约交易（USDT 结算），支持 1-20 倍杠杆。\n ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2268446","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4020","IE00BZ1G4Q59.USD","IE00BMPRXR70.SGD","NVOH","NOK","LU0154236417.USD","LU1093756325.SGD","NVO","BK4588","BK4599","BK4532","LNOK","BK4007","IE00BMPRXN33.USD","NVOX","BK4585","IE00BKVL7J92.USD","GATE","LU1093756168.USD","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639626600","title":"诺和诺德：印度批准维格维用于青少年群体","url":"https://stock-news.laohu8.com/highlight/detail?id=2639626600","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639626600?lang=zh_cn&edition=full","pubTime":"2026-05-29 17:56","pubTimestamp":1780048560,"startTime":"0","endTime":"0","summary":"诺和诺德印度公司向彭博社书面回应称，印度中央药品标准管控局已批准爆款减肥药Wegovy 上市，适用人群为12周岁及以上、体重超60公斤（132磅） 的青少年。\n 该企业表示，儿童肥胖问题日益严峻，已成为一大公共健康难题，且会带来长期健康隐患；该药物的使用须由医护人员评估判定。\n 药企同时指出，这款药物针对青少年的用药剂量与售价将和成人版本保持一致。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：刘明亮","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-29/doc-inhzqimp7582428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["NVO","BK4007","LU1093756325.SGD","BK4585","LU0154236417.USD","LU1093756168.USD","BK4599","NVOH","BK4532","NVOX","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164391230","title":"异动解读｜诺和诺德盘中上涨3.18%，EASL大会MASH数据发布叠加收购传闻提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1164391230","media":"行情直击","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164391230?lang=zh_cn&edition=full","pubTime":"2026-05-28 22:43","pubTimestamp":1779979415,"startTime":"0","endTime":"0","summary":"5月28日，诺和诺德盘中上涨3.18%，报45.965美元/股，成交额2.53亿美元。消息面上，多重利好共振推动股价走强。首先，诺和诺德正参加EASL 2026肝病年会，集中发布司美格鲁肽2.4mg治疗MASH的关键三期ESSENCE试验核心数据，其中37%患者肝纤维化改善的疗效数据受市场关注。其次，市场传出诺和诺德拟收购丹麦上市公司Zealand Pharma，以补齐胰淀素及双受体靶点布局，增强对礼来的竞争优势。同日制药板块GLP-1赛道整体走强，礼来亦上涨5.56%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637434972","title":"诺和诺德高剂量Wegovy单剂量注射笔获欧盟CHMP积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2637434972","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637434972?lang=zh_cn&edition=full","pubTime":"2026-05-23 03:00","pubTimestamp":1779476452,"startTime":"0","endTime":"0","summary":"诺和诺德于5月22日宣布，欧洲药品管理局人用药品委员会已采纳积极意见，推荐批准Wegovy 7.2 mg单剂量注射笔在欧盟上市，用于成人肥胖症患者的体重管理。此次获批的单剂量注射笔将三针合为一体，大幅提升了用药便利性。 诺和诺德预计将于2026年第三季度在欧盟正式推出Wegovy 7.2 mg单剂量注射笔。该产品已在美国以Wegovy HD品牌名上市销售。受此消息提振，诺和诺德股价当日上涨约2.4%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-23/doc-inhyvhtw8043890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["NVOX","BK4007","IE00BZ1G4Q59.USD","BK4532","BK4588","NVO","IE00BKVL7J92.USD","LU1093756168.USD","LU0154236417.USD","NVOH","LU1093756325.SGD","BK4585","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637334393","title":"诺和诺德(NVO)Wegovy获欧洲背书 GLP1赛道竞争持续升温","url":"https://stock-news.laohu8.com/highlight/detail?id=2637334393","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637334393?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:58","pubTimestamp":1779461893,"startTime":"0","endTime":"0","summary":"在此之前，Wegovy的每周皮下注射剂型已在欧洲获批上市，用于体重管理。早在去年12月，该药物已获美国FDA批准，诺和诺德也于今年正式将其推向美国口服减肥药市场。除诺和诺德外，药企礼来的每日口服减重疗法Foundayo也已登陆美国市场，两大药企形成正面竞争格局。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300754","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0154236417.USD","BK4007","NVO","BK4585","IE00BKVL7J92.USD","LU1093756325.SGD","BK4532","LU1093756168.USD","NVOH","IE00BZ1G4Q59.USD","BK4599","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637336886","title":"减重神药或能抑制癌症发展，诺和诺德、礼来迎重磅利好","url":"https://stock-news.laohu8.com/highlight/detail?id=2637336886","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637336886?lang=zh_cn&edition=full","pubTime":"2026-05-22 06:52","pubTimestamp":1779403947,"startTime":"0","endTime":"0","summary":"四项覆盖数十万患者的研究显示，Ozempic（司美格鲁肽）、Mounjaro（替尔泊肽）等明星减肥药或能抑制癌症发展——肺癌进展率近乎减半，乳腺癌五年生存率从89.5%跃升至95%以上。研究人员指出，现有证据仅显示关联性，而非因果关系。若抗癌效益最终获证，将再度重塑诺和诺德与礼来的医学与商业版图。","market":"sg","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e7a4338b1034ad785d5025385d8625c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3772873","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","LU0889565916.HKD","LU2750360997.AUD","LU0234572021.USD","LU0786609619.USD","IE0009355771.USD","IE00BJT1NW94.SGD","LU0964807845.USD","LU2089283258.USD","LU1974910355.USD","LU2168564495.EUR","SG9999013999.USD","LU2750360641.GBP","LU0266013472.USD","LU0787776722.HKD","LU1814569148.SGD","BK4516","LU2237443622.USD","LU2324357040.USD","LU1988902786.USD","LU2023250504.SGD","LU0203202063.USD","NVOH","LU1868836914.USD","IE00BJJMRX11.SGD","LU2087625088.SGD","SGXZ99366536.SGD","LU2237443549.SGD","LU1868837300.USD","LU2896262040.SGD","LU1280957306.USD","LU1127390331.HKD","LU0238689110.USD","LU2265009873.SGD","LU2756315318.SGD","LU0640476718.USD","IE0005OL40V9.USD","SG9999014906.USD","LU1057294990.SGD","LU1551013342.USD","SG9999015978.USD","LU0466842654.USD","LU0471298777.SGD","LU1548497426.USD","IE0004445015.USD","LU1069344957.HKD","LU1623119135.USD","LU1712237335.SGD","LU1551013425.SGD","LU1061106388.HKD","LU2491049909.HKD","LU0154236417.USD","BK4585","LU2168564149.EUR","LU0823434740.USD","SGXZ81514606.USD","LU1291159041.SGD","LU0689472784.USD","LU2271345857.HKD","LLYX","ELIS","SG9999015945.SGD","SG9999015952.SGD","LU0320765059.SGD","IE0002141913.USD","BK4532","IE0004445239.USD","LU0079474960.USD","LU2237438978.USD","SG9999018865.SGD","LU2236285917.USD","SG9999015986.USD","LU0820561909.HKD","SG9999001176.USD","SGXZ31699556.SGD","LU2168564222.USD","LU2491050154.USD","LU2746668461.USD","IE00BJJMRZ35.SGD","LU2417539215.USD","IE00BK4W5L77.USD","LU2468319806.SGD","IE00B1XK9C88.USD","IE00BFSS8Q28.SGD","LU0122379950.USD","LU2361044865.SGD","LU2491050071.SGD","LU2361045086.USD","LU2111349929.HKD","SG9999018857.SGD","LU1323610961.USD","IE00BKDWB100.SGD","LU0114720955.EUR","LU0385154629.USD","LU2360106947.USD","LU0256863902.USD","LU2028103732.USD","LU0210536198.USD","LU2168564065.EUR","SG9999014914.USD","LU0289739699.SGD","LU0198837287.USD","IE00BN29S564.USD","LU0353189680.USD","LU2462157665.USD","LU1629891620.HKD","LU0094547139.USD","LU2471134952.CNY","LU2456880835.USD","IE0001KFT4U8.USD","LU0417517546.SGD","LU1917777945.USD","BK4533","IE00B775H168.HKD","LU0323591593.USD","LU2264538146.SGD","LU2357305700.SGD","IE00B2B36J28.USD","LU0096364046.USD","LU2213496289.HKD","LU2108987350.USD","IE00B4JS1V06.HKD","LU0256863811.USD","LU2471134523.USD","LU2237443382.USD","LU0354030438.USD","LU2237443978.SGD","LU2552382215.SGD","LU2023251221.USD","LU2602419157.SGD","LU1093756168.USD","LU2746668974.SGD","SG9999001176.SGD","LU1093756325.SGD","LU0456855351.SGD","GB00BDT5M118.USD","SGXZ57979304.SGD","LU1868837136.USD","LU0820561818.USD","LU1145028129.USD","BK4534","LU1035775433.USD","LLY","LU1023059063.AUD","LU1804176565.USD","LU2063271972.USD","SGXZ51526630.SGD","LU0061475181.USD","LU2361044949.HKD","NVOX","LU0823434583.USD","LU2089284900.SGD","LU1720051108.HKD","LU2552382058.USD","LU0133085943.USD","LU1720051017.SGD","IE00BFSS7M15.SGD","NVO","LU2552382132.HKD","IE00BJLML261.HKD","IE00B4R5TH58.HKD","LU0225283273.USD","LU0708995401.HKD","BK4581","IE00BZ1G4Q59.USD","IE00BJJMRY28.SGD","LU1232071149.USD","LU0823416689.USD","BK4007","LU1989771016.USD","LU2461242641.AUD","LU2471134796.USD","LU1868836591.USD","LU0109391861.USD","LU0672654240.SGD","LU0471298694.HKD","LLII","IE00B1BXHZ80.USD","LU0320765992.SGD","LU1267930730.SGD","LU0943347566.SGD","IE00BWXC8680.SGD","LU2237443465.HKD","LU1366192091.USD","LU0203201768.USD","LU0820562030.AUD","LU0058720904.USD","SG9999017495.SGD","LU0158827781.USD","LU1868836757.USD","LU0006306889.USD","IE00BFTCPJ56.SGD","IE00BKPKM429.USD","LU0106261372.USD","LU0354030511.USD","LU2023250330.USD","LU0316494557.USD","LU0353189763.USD","LU2471134879.HKD","IE00BK4W5M84.HKD","SG9999014898.SGD","LU1064131342.USD","LU2237443895.HKD","LU2106854487.HKD","LU2168563687.JPY","LU0158827948.USD","IE00BKVL7J92.USD","LU2089984988.USD","LU0432979614.USD","LU1983299246.USD","LU0882574139.USD","LU2211815571.USD","LU0683600562.USD","LU0097036916.USD","ELIL","LU2112291526.USD","LU0109394709.USD","IE00B7KXQ091.USD","LU2756315664.SGD","LLYZ","SG9999014880.SGD","BK4588","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636028536","title":"诺和诺德计划推动Wegovy口服减肥药登陆美国以外市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2636028536","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636028536?lang=zh_cn&edition=full","pubTime":"2026-05-18 15:40","pubTimestamp":1779090023,"startTime":"0","endTime":"0","summary":"诺和诺德透露，随着减肥药市场的全球争夺战愈演愈烈，公司正准备全力推动旗下Wegovy口服减肥药登陆美国以外市场。 目前诺和诺德及其主要竞争对手礼来制药，过半以上销售额都来自美国市场。 拉森并未透露Wegovy口服药首批出海上市的具体国家，只表示药企会依照市场潜力进行布局，同时会考量当地肥胖症患者需求、医生专业素养以及远程医疗合作资源等条件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-18/doc-inhyiewm2822146.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["NVOX","IE00BKVL7J92.USD","LU1093756168.USD","LU1093756325.SGD","NVO","BK4585","BK4588","BK4532","BK4007","BK4599","NVOH","LU0154236417.USD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635842857","title":"减重赛道激战正酣：跨国巨头齐亮剑，竞争升维至全病程管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2635842857","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635842857?lang=zh_cn&edition=full","pubTime":"2026-05-13 19:54","pubTimestamp":1778673240,"startTime":"0","endTime":"0","summary":"在2026年世界防治肥胖日到来、“体重管理年”行动收官的关键节点，全球减重药物市场的火药味达到了新的浓度。从伊斯坦布尔第33届欧洲肥胖大会（ECO），到国内学术峰会，诺和诺德、礼来以及辉瑞/先为达等跨国药企与本土创新力量，不约而同地选择在这一时间窗口密集“亮剑”，发布了各自在减重领域的最新重磅数据。这并非巧合。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605133736129640.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133736129640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","IE000M9KFDE8.USD","LU0306807586.USD","PFE","IE00BZ1G4Q59.USD","SG9999011175.SGD","IE00BKVL7J92.USD","BK4585","IE00BLSP4239.USD","LU0225771236.USD","LU1057294990.SGD","BK4534","IE00BBT3K403.USD","LU0985481810.HKD","SG9999002232.USD","BK4144","LU1894683264.USD","SGXZ57979304.SGD","LU0997586861.USD","LU0321505439.SGD","BK4532","IE00BLSP4452.SGD","LU0234572021.USD","IE00B19Z3B42.SGD","SG9999001176.SGD","BK4550","LU0868494617.USD","IE00B19Z3581.USD","LU1023059063.AUD","LU1883839398.USD","ECO","BK4581","NVO","BK4007","NVOX","BK4533","LU1066053197.SGD","LU0289739699.SGD","BK4568","LU0456855351.SGD","IE0002270589.USD","SG9999003800.SGD","SG9999001176.USD","BK4592","LU0154236417.USD","LU0225284248.USD","LU1093756325.SGD","LU0058720904.USD","LU1894683348.USD","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137321098","title":"市场聚焦：游戏驿站、Venture Global、温蒂汉堡、Hims & Hers等个股动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1137321098","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137321098?lang=zh_cn&edition=full","pubTime":"2026-05-12 20:09","pubTimestamp":1778587787,"startTime":"0","endTime":"0","summary":"游戏驿站 ：这家视频游戏零售商的董事会拒绝了eBay主动提出的560亿美元收购要约，其股价在盘前交易中应声下跌。Venture Global ：这家液化天然气出口商报告第一季度营收和利润大幅增长后，其股价在盘前交易中上涨了9%。Hims & Hers ：这家远程医疗平台的股价在盘前下跌了15%，原因是该公司表示，其调整减肥产品线的举措推高了成本。ZoomInfo Technologies Inc. ：这家市场情报公司的股价在周一晚些时候下调全年业绩指引后大幅下挫。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c1ee3020066801ecc9807d71c3848eaf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4209","GME","BK4577","HIMS","GPRO","HIYY","UA","NVO","NVOH","BK4202","BK4213","LU1093756168.USD","NVOX","WEN","BK4077","BK4076","BK4599","GTM","HIMZ","LU0154236417.USD","BK4007","BK4532","BAYRY","BK4585","BK4588","BK4196","LU1093756325.SGD","IGME","GMEY","BK4547","HIMY","BK4078","IE00BKVL7J92.USD","HMYY","BK4023","IE00BZ1G4Q59.USD","GMEU","VG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110023794","title":"关注焦点：Venture Global、Hims & Hers、GoPro等个股动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1110023794","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110023794?lang=zh_cn&edition=full","pubTime":"2026-05-12 17:18","pubTimestamp":1778577489,"startTime":"0","endTime":"0","summary":"液化天然气出口商Venture Global Inc. 将于今日早间公布财报。由于霍尔木兹海峡关闭，该公司有望从中受益，其业绩或将揭示当前市场需求的实际强度。该股在盘前交易中已出现上涨。远程医疗平台Hims & Hers Health Inc. 的股价在盘前重挫逾15%。此前，该公司表示，其对减肥产品线的调整重组导致成本上升。运动品牌Under Armour 和On Holding AG 预计将于今日发布财报。市场情报公司ZoomInfo Technologies Inc. 股价暴跌。该公司于周一晚间下调了其全年业绩指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2265009873.SGD","BK4023","BK4202","BK4547","IE00BKVL7J92.USD","HIYY","BK4196","BK4599","HMYY","LU1804176565.USD","LU1093756325.SGD","BK4532","GPRO","BK4078","IE00BZ1G4Q59.USD","BK4585","GTM","LU0289961442.SGD","BK4588","BK4007","HIMS","HIMY","LU0472753341.HKD","BK4146","LU0069063385.USD","NVO","BK4213","VG","HIMZ","LU0057025933.USD","LU0289739343.SGD","BAYRY","NVOH","UA","ONON","LU1093756168.USD","BK4077","NVOX","LU0511384066.AUD","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634260647","title":"扎克伯格投资生物药企拿下诺和诺德细胞疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2634260647","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634260647?lang=zh_cn&edition=full","pubTime":"2026-05-12 14:42","pubTimestamp":1778568166,"startTime":"0","endTime":"0","summary":"细胞疗法等先进生物技术力量正在向新兴AI医疗公司转移。当地时间5月11日，一家成立仅两年多的生物技术公司CellularIntelligence宣布收购丹麦制药巨头诺和诺德的一款在研的帕金森细胞疗法。CellularIntelligence是由硅谷巨头Meta公司创始人扎克伯格投资的一家由人工智能驱动的细胞疗法公司，在早期融资中曾获得扎克伯格等投资人超过6000万美元的资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605123734394252.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734394252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NVOX","BK4588","LU1093756168.USD","LU1093756325.SGD","NVO","IE00BKVL7J92.USD","BK4599","LU0154236417.USD","BK4585","BK4007","META","BK4532","NVOH","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633045582","title":"诺和诺德(NVO.US)在印度降价后 减肥药销量4月激增40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633045582","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633045582?lang=zh_cn&edition=full","pubTime":"2026-05-08 19:52","pubTimestamp":1778241130,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺和诺德上月印度糖尿病及减肥药物销量激增40%，起因是大幅降价显著提振了其品牌药物需求——尽管仿制GLP-1疗法正大量涌入市场。自4月1日起，诺和诺德将两种药物起始剂量价格分别下调36%和48%，使价格降至5660卢比。尽管礼来公司在经历早期挫折后仍保持印度GLP-1药物销量领先地位，但这些低价仿制药的销量推动4月市场环比激增56%，总量达41.4万剂。截至目前，诺和诺德和礼来公司代表未对此事作出回应。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0154236417.USD","BK4007","BK4532","NVOH","BK4585","IE00BKVL7J92.USD","BK4588","LU1093756168.USD","NVOX","LU1093756325.SGD","BK4599","IE00BZ1G4Q59.USD","NVO"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2633410627","title":"跨国药企开门红 巨头领跑减重赛道 “王牌”产品成增长胜负手","url":"https://stock-news.laohu8.com/highlight/detail?id=2633410627","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633410627?lang=zh_cn&edition=full","pubTime":"2026-05-08 07:52","pubTimestamp":1778197920,"startTime":"0","endTime":"0","summary":"【跨国药企开门红 巨头领跑减重赛道 “王牌”产品成增长胜负手】有券商医药行业分析师对21世纪经济报道记者表示，当前跨国药企的业绩已高度“超级重磅药化”，手握“王牌”产品足以决定公司的增长、估值乃至战略走向。纵观财报数据，一个清晰的信号也正在浮现：在专利悬崖、政策博弈与市场竞争的多重挑战中，如何深度挖掘并战略性运营核心大单品，已从“增长选择”演变为“生存命题”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605083730569459.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605083730569459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU1929549753.HKD","LU2125154935.USD","LU0289739699.SGD","LU2361044865.SGD","SG9999001440.SGD","IE00BN8TJ469.HKD","NVOX","LU2361045086.USD","IE00BJJMRZ35.SGD","LU2468319806.SGD","BK4007","LU1941712264.USD","NVOH","BK4550","LU0211331839.USD","LU1941712348.USD","SG9999014567.USD","LU2112291526.USD","SG9999001176.USD","SG9999002224.SGD","SG9999013999.USD","BK4588","LU0203347892.USD","LU1066051811.HKD","LU1023059063.AUD","LU1035773651.USD","LU0942090050.USD","LU1989772923.USD","LU0130102774.USD","LU2491049909.HKD","LU1069347547.HKD","LU1291159041.SGD","SG9999001176.SGD","LU1061106388.HKD","LU1093756325.SGD","SGXZ57979304.SGD","IE00BBT3K403.USD","LU1585245621.USD","LU2089984988.USD","IE000M9KFDE8.USD","IE00B2B36J28.USD","LU0006306889.USD","LU0965509101.SGD","SG9999002232.USD","LU2357627491.SGD","LU0070302665.USD","SG9999014575.USD","BK4532","SG9999015358.SGD","LU2360032135.SGD","BK4533","LU0058720904.USD","LU0320765646.SGD","LU1116320901.HKD","LU1934455194.USD","IE00BZ1G4Q59.USD","LU1917777945.USD","SG9999015341.SGD","MRK","LU2023250504.SGD","LU0265550359.USD","LU0266013472.USD","LU2491050154.USD","LU0432979614.USD","LU0980610538.SGD","LU1037948541.HKD","LU2361044949.HKD","LU0098860793.USD","LU0130517989.USD","LU0965508806.USD","LU0965509010.AUD","LU0122379950.USD","LU0203345920.USD","LU0648001328.SGD","LU2125154778.USD","LU1093756168.USD","LU1162221912.USD","BK4585","LU0265550946.USD","LU0106261372.USD","LU1201861249.SGD","LU0868494617.USD","IE00BJT1NW94.SGD","LU0477156953.USD","SG9999014559.SGD","LU1057294990.SGD","SNY","LU0965509283.SGD","IE00BLSP4452.SGD","BK4599","LLY","LU0154236417.USD","LU0320765489.SGD","IE00B1BXHZ80.USD","LU1934455277.USD","IE0002141913.USD","LU1989772840.SGD","LU1989771016.USD","LU0985320562.USD","IE00BKVL7J92.USD","LU1037948897.HKD","LU2106854487.HKD","LU1983299246.USD","IE00BSNM7G36.USD","LU0208291251.USD","SG9999014542.SGD","LU1066051498.USD","LU1116320737.USD","LU0238689110.USD","LU0861579265.USD","LU1066051225.USD","LU1066053197.SGD","LU1934455863.HKD","BK4534","LU2023250843.SGD","BK4516","BK4559","LU0234572021.USD","LU1699723380.USD","LU2324357040.USD","LU1974910355.USD","IE00BLSP4239.USD","LU0859254822.USD","LU1430594728.SGD","LU0868494708.USD","IE0009355771.USD","LU1571399168.USD","LU2491050071.SGD","NVO","LU2461242641.AUD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":-0.0575},{"period":"1month","weight":-0.0612},{"period":"3month","weight":0.1135},{"period":"6month","weight":-0.1024},{"period":"1year","weight":-0.4087},{"period":"ytd","weight":-0.1557}],"compareEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":0.0051},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.0756},{"period":"1year","weight":0.2437},{"period":"ytd","weight":0.0816}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球性的医疗保健公司，也是肥胖和糖尿病护理、制造和营销包括GLP-1受体激动剂和现代胰岛素在内的医药产品的世界领先企业。总部位于丹麦，业务遍及约80个国家，产品销往约170个国家。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.120105},{"month":2,"riseRate":0.6,"avgChangeRate":0.019219},{"month":3,"riseRate":0.444444,"avgChangeRate":0.006415},{"month":4,"riseRate":0.622222,"avgChangeRate":0.018023},{"month":5,"riseRate":0.565217,"avgChangeRate":0.019713},{"month":6,"riseRate":0.673913,"avgChangeRate":0.024352},{"month":7,"riseRate":0.488889,"avgChangeRate":-0.001692},{"month":8,"riseRate":0.533333,"avgChangeRate":0.006145},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.002979},{"month":10,"riseRate":0.488889,"avgChangeRate":-0.004606},{"month":11,"riseRate":0.6,"avgChangeRate":0.026574},{"month":12,"riseRate":0.733333,"avgChangeRate":0.048757}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}